Arbutus Biopharma CorpABUS
Price$4.78

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $181.7M+2,844.7% YoYTTM through 30 Jun 2026
Net Income $153.1MTTM through 30 Jun 2026
Free Cash Flow -$24.9MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin82.6%
Operating Margin94.4%
Net Margin84.2%

Returns

61.8%ROE
58.0%ROA
63.9%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio54.26x
Net Debt-$95.2Mnet cash position
Cash & Equivalents$19.2M

Quality Metrics

Altman Z-Score36.37
Piotroski F-Score4 / 9
FCF Margin-13.7%
Rule of 4025.4
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $14.1M
Diluted EPS$0.79TTM
'18'20'21'22'23'24'25
FY2025: $-0.17

Dividend

No dividend

Capital Allocation

R&D Spend$17.8M
Capex Intensity0.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.